Short answer
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on August 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026 announced on August 5, 2026.
CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced on August 5, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 GAAP net income $28 million, versus a $10.6 million loss, marking a material profitability inflection
- Revenue $743.2 million, up 55.6%, with Medicare Advantage membership up 48.7% to 156,840
- Adjusted EBITDA $40.9 million, up 139.2%, while adjusted SG&A margin improved to 15.1% from 17.3%
- Insurance BER improved to 87.6% from 88.4%, supporting stronger medical economics despite rapid membership growth
- 2026 guidance raised: revenue $2.92 billion to $3.00 billion, GAAP net income $20 million to $35 million, Adjusted EBITDA $70 million to $85 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings
Get the next CLOV 8-K as it lands
Follow CLOV for push alerts, or ask the research agent what this filing means.